摘要
目的探讨苍耳子鼻炎滴丸联合色甘萘甲那敏鼻喷雾剂治疗成人过敏性鼻炎患者的临床效果。方法选取2018年1月至2019年1月北部战区总医院收治的成人过敏性鼻炎患者155例作为研究对象,按照治疗方案不同分为对照组(75例)与观察组(80例)。对照组仅给予色甘萘甲那敏鼻喷雾剂治疗,观察组联合苍耳子鼻炎滴丸治疗,比较两组临床症状积分、治疗效果、炎症介质水平及不良反应。结果治疗后,观察组鼻塞、喷嚏、流涕、鼻痒症状积分及总症状积分显著低于对照组,差异有统计学意义(P<0.05);观察组治疗有效率为90.00%,显著高于对照组的77.33%,差异有统计学意义(P<0.05);治疗后,观察组白细胞介素-10(IL-10)、免疫球蛋白E(IgE)显著低于对照组,差异有统计学意义(P<0.05);两组患者未出现明显不良反应,差异无统计学意义(P>0.05)。结论苍耳子鼻炎滴丸联合色甘萘甲那敏鼻喷雾剂可以显著改善成人过敏性鼻炎患者临床症状,疗效显著,且具有较高的安全性。
Objective To observe the clinical effects of Cangerzi Drops Pills combined with Cereglenamine Nasal Sprayer in the treatment of adult allergic rhinitis.Methods A total of 155 adult patients with allergic rhinitis admitted to Northern Theater General Hospital from January 2018 to January 2019 were selected as the research objects and were divided into a study group and a control group according to different treatment regimens.The control group(n=75)was only treated with the nasal spray of trygannonalin,and the research group(n=80)was combined with Cangerzi Dropping Pills.The clinical symptom score,therapeutic effect,inflammatory factor levels and adverse reactions were compared between the 2 groups.Results After treatment,the symptom scores of nasal congestion,sneezing,runny nose,nasal itching and total symptom scores in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).The effective rate of the observation group was 90.00%,which was significantly higher than 77.33%of the control group(P<0.05).After treatment,the interleukin-10(IL-10)and immunoglobulin E(IgE)of the observation group were significantly lower than those of the control group,with a statistically significant difference(P<0.05);there were no obvious adverse reactions in the two groups,and the difference was not statistically significant(P>0.05).Conclusion Cangerzi Dropping Pills combined with Cromanthalamine Nasal Spray can significantly improve the clinical symptoms of adult allergic rhinitis patients,with significant curative effect and high safety.
作者
石彬
SHI Bin(Department of Otolaryngology,Northern Theater General Hospital,Shenyang 110005,China)
出处
《中国药物经济学》
2022年第3期69-72,共4页
China Journal of Pharmaceutical Economics